Experience from a large multi-centre expanded access programme (EAP) with gefitinib ('Iressa', ZD1839) as monotherapy in advanced non-small cell lung cancer (NSCLC)

van Puijenbroek, R.; Bosquee, Léon; Tits, G.; Germonpre, P.; Strobbe, E.; Vansteenkiste, J.

Paper published in a journal (Scientific congresses and symposiums)

van Puijenbroek, R.; Bosquee, Léon; Tits, G. et al.

2005 • In Lung Cancer, 49 (Suppl. 2), p. 273

Peer Reviewed verified by ORBi

Permalink
https://hdl.handle.net/2268/83003

Files (1)Send to Details Statistics Bibliography Similar publications

Files

Full Text

Experience from a large multi-centre expanded access programme (EAP) with gefitinib ('Iressa', ZD1....pdf

Publisher postprint (301.01 kB)

Download

All documents in ORBi are protected by a user license.

Send to

RIS BibTex APA Chicago Permalink X Linkedin

Details

Disciplines :

Cardiovascular & respiratory systems
Oncology

Author, co-author :

van Puijenbroek, R.

Bosquee, Léon ; Centre Hospitalier Universitaire de Liège - CHU > Pneumologie-Allergologie

Tits, G.

Germonpre, P.

Strobbe, E.

Vansteenkiste, J.

Language :

English

Title :

Experience from a large multi-centre expanded access programme (EAP) with gefitinib ('Iressa', ZD1839) as monotherapy in advanced non-small cell lung cancer (NSCLC)

Publication date :

July 2005

Audience :

International

Journal title :

Lung Cancer

ISSN :

0169-5002

eISSN :

1872-8332

Publisher :

Elsevier Ireland Ltd, Clare, Ireland

Volume :

Issue :

Suppl. 2

Pages :

S273

Peer reviewed :

Peer Reviewed verified by ORBi

Available on ORBi :

since 27 January 2011

Statistics

Number of views

29 (1 by ULiège)

Number of downloads

63 (1 by ULiège)

More statistics